Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.44 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634259 | 0.88 | CHRNB2 (0.42) | L3MBTL1MEN1KMT2ATDP1CHRNB2 | |
| SCHEMBL18557477 | 0.88 | L3MBTL1 (0.58) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL10291288 | 0.85 | L3MBTL1 (0.65) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL8418308 | 0.83 | BLM (0.43) | L3MBTL1MEN1KMT2ATDP1CHRNB2 | |
| SCHEMBL674671 | 0.82 | — | — | |
| SCHEMBL10663507 | 0.82 | L3MBTL1 (0.58) | L3MBTL1MEN1KMT2ATDP1CHRNB2 | |
| SCHEMBL12351548 | 0.79 | SIGMAR1 (0.41) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL12197867 | 0.79 | RAB9A (0.41) | L3MBTL1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL805507 | 0.78 | GNAI3 (0.50) | L3MBTL1MEN1KMT2ATDP1CHRNB2 | |
| SCHEMBL9762642 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580425-B2 | Pyrido[3,4-b] indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9271971-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150352087-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9199996-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2670764-B1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9085580-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9079904-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20090075986-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | NKUADA, LLC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080319044-A1 | Compounds and Methods of Use Thereof | NUADA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080187978-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-08-07 | — | — | US | disclosed |
| US-20080132506-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-06-05 | — | — | US | disclosed |
| US-20080064688-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-03-13 | — | — | US | disclosed |
| US-7342037-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064688-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | L3MBTL1 4056/4885MEN1 4863/4885KMT2A 3925/4885 |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | TNF, IL1B, TNFRSF1A | L3MBTL1 3581/4885MEN1 1183/4885KMT2A 4122/4885 |
| US-20090105230-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | L3MBTL1 4056/4885MEN1 4863/4885KMT2A 3925/4885 |
| US-20090075986-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | L3MBTL1 4056/4885MEN1 4863/4885KMT2A 3925/4885 |
| US-20070037808-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | L3MBTL1 1627/4885MEN1 4811/4885KMT2A 3389/4885 |
| US-20080132506-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | L3MBTL1 4056/4885MEN1 4863/4885KMT2A 3925/4885 |
| US-20150352087-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | L3MBTL1 4349/4885MEN1 3074/4885KMT2A 1323/4885 |
| US-20080319044-A1 | Compounds and Methods of Use Thereof | TNF, LITAF, LTA | L3MBTL1 2926/4885MEN1 1141/4885KMT2A 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.